• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Rosemary Foster, Ph.D.


  • Bradford LS, Rauh-Hain A, Clark RM, Groeneweg JW, Zhang L, Borger D, Zukerberg LR, Growdon WB, Foster R, Rueda BR.Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.Gynecol Oncol. 2014 May;133(2):346-52.
  • Groeneweg JW, Hall TR, Zhang L, Kim M, Byron VF, Tambouret R, Sathayanrayanan S, Foster R, Rueda BR, Growdon WB.Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.Gynecol Oncol. 2014 Mar 22.
  • Kulkarni-Datar K, Orsulic S, Foster R, Rueda BR.Ovarian tumor initiating cell populations persist following paclitaxel and carboplatin chemotherapy treatment in vivo.Cancer Lett. 2013 Oct 10;339(2):237-46.
  • Foster R, Buckanovich RJ, Rueda BR.Ovarian cancer stem cells: Working towards the root of stemness.Cancer Lett. 2012 Nov 5.
  • Growdon WB, Roussel BN, Scialabba VL, Foster R, Dias-Santagata D, Iafrate AJ, Ellisen LW, Tambouret RH, Rueda BR, Borger DR.Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.Gynecol Oncol. 2011 Apr;121(1):212-7.
  • Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR.Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells.Reprod. Biol. Endocrinol. 2010;8:147.
  • Curley MD, Garrett LA, Schorge JO, Foster R, Rueda BR.Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer.Front Biosci. 2011;16:368-92.
  • Kaplan L, Foster R, Shen Y, Parry DM, McMaster ML, O'Leary MC, Gusella JF.Monozygotic twins discordant for neurofibromatosis 1.Am J Med Genet A. 2010 Mar;152A(3):601-6.
  • Curley MD, Therrien VA, Cummings CL, Sergent PA, Koulouris CR, Friel AM, Roberts DJ, Seiden MV, Scadden DT, Rueda BR, Foster R.CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.Stem Cells. 2009 Dec;27(12):2875-83.
  • Sakamoto H, Friel AM, Wood AW, Guo L, Ilic A, Seiden MV, Chung DC, Lynch MP, Serikawa T, Munro E, Oliva E, Orsulic S, Kirley SD, Foster R, Zukerberg LR, Rueda BR.Mechanisms of Cables 1 gene inactivation in human ovarian cancer development.Cancer Biol Ther. 2008 Feb;7(2):180-88.
  • Jiang W,Betson M,Mulloy R,Foster R,Levay M,Ligeti E,Settleman J.p190A RhoGAP is a glycogen synthase kinase-3-beta substrate required for polarized cell migration.J Biol Chem. 2008 Jul 25;283(30):20978-88.
  • Friel AM, Sergent PA, Patnaude C, Szotek PP, Oliva E, Scadden DT, Seiden MV, Foster R, Rueda BR.Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cells.Cell Cycle. 2008 Jan;7(2):242-9.
  • Duan Z, Bradner J, Greenberg E, Mazitschek R, Foster R, Mahoney J, Seiden MV.8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.Mol Pharmacol. 2007 Nov;72(5):1137-45.
  • Duan Z, Bradner JE, Greenberg E, Levine R, Foster R, Mahoney J, Seiden MV.SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation.Clin Cancer Res. 2006 Nov 15;12(22):6844-52.
  • Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hampel C, Lee H, Seiden MV.Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.Clin Cancer Res. 2006 Sep 1;12(17):5055-63.
  • Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK.Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11154-9.
  • Chirnomas D, Taniguchi T, de la Vega M, Vaidya AP, Vasserman M, Hartman AR, Kennedy R, Foster R, Mahoney J, Seiden MV, D'Andrea AD.Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway.Mol Cancer Ther. 2006 Apr;5(4):952-61.
  • Foster R, Solano S, Mahoney J, Fuller A, Oliva E, Seiden MV.Reclassification of a tubal leiomyosarcoma as an eGIST by molecular evaluation of c-KIT.Gynecol Oncol. 2006 May;101(2):363-6.
  • Duan Z, Foster R, Brakora KA, Yusuf RZ, Seiden MV.GBP1 overexpression is associated with a paclitaxel resistance phenotype.Cancer Chemother Pharmacol. 2006 Jan;57(1):25-33.
  • Okuda K, Foster R, Griffin JD.Signaling domains of the beta c chain of the GM-CSF/IL-3/IL-5 receptor.Ann N Y Acad Sci. 1999 Apr 30;872:305-12; discussion 312-3.
  • Okuda K, Smith L, Griffin JD, Foster R.Signaling functions of the tyrosine residues in the betac chain of the granulocyte-macrophage colony-stimulating factor receptor.Blood. 1997 Dec 15;90(12):4759-66.